Small-molecule activators of SIRT5 (to increase malonylation removal) or agents that reduce malonyl-CoA levels in tissues (such as ACC inhibitors or MCD activators) could correct the excessive protein malonylation observed in metabolic syndrome. This evidence concerns the gene SIRT5 and metabolic syndrome.